Share This Page
Drug Price Trends for NDC 00378-6380
✉ Email this page to a colleague
Average Pharmacy Cost for 00378-6380
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VERAPAMIL ER 180 MG CAPSULE | 00378-6380-01 | 1.98530 | EACH | 2026-03-18 |
| VERAPAMIL ER 180 MG CAPSULE | 00378-6380-01 | 2.29606 | EACH | 2026-02-18 |
| VERAPAMIL ER 180 MG CAPSULE | 00378-6380-01 | 2.20680 | EACH | 2026-01-21 |
| VERAPAMIL ER 180 MG CAPSULE | 00378-6380-01 | 1.98482 | EACH | 2025-12-17 |
| VERAPAMIL ER 180 MG CAPSULE | 00378-6380-01 | 1.81337 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00378-6380
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections forNDC: 00378-6380
Executive Summary
This report analyzes the market landscape for the pharmaceutical product identified by National Drug Code (NDC) 00378-6380. The analysis focuses on current market penetration, key drivers of demand, competitive positioning, and projected pricing trends. The product is primarily indicated for [Insert Primary Indication], a condition with a growing patient population due to [Insert Key Demand Driver 1] and [Insert Key Demand Driver 2]. Current market share is estimated at [Insert Market Share Percentage]% within its therapeutic class. Key competitors include [Competitor Drug 1] and [Competitor Drug 2]. Price projections indicate a [Increase/Decrease/Stable Trend] over the next five years, influenced by patent expiry, generic entry, and evolving reimbursement policies.
What is the Therapeutic Indication and Mechanism of Action for NDC: 00378-6380?
NDC 00378-6380 is a [Drug Class, e.g., small molecule, biologic] prescribed for the treatment of [Specific Disease/Condition, e.g., moderate to severe plaque psoriasis, chronic obstructive pulmonary disease]. Its mechanism of action involves [Describe Mechanism of Action, e.g., selective inhibition of the Janus kinase (JAK) pathway, modulation of tumor necrosis factor-alpha (TNF-α) activity]. This action targets the underlying pathophysiology of the disease by [Explain downstream effects, e.g., reducing inflammatory cytokine production, promoting immune cell differentiation]. The established efficacy and safety profile, as demonstrated in clinical trials [Cite a key study, e.g., (Smith et al., 2020)], supports its role in [Briefly state treatment goal, e.g., achieving sustained remission, improving lung function].
Who are the Key Manufacturers and Distributors?
The primary manufacturer and marketer of NDC 00378-6380 is [Manufacturer Name]. This entity holds the original New Drug Application (NDA) [Cite FDA approval date, e.g., approved by the U.S. Food and Drug Administration (FDA) on YYYY-MM-DD]. Distribution channels are primarily managed through [List primary distribution channels, e.g., major pharmaceutical wholesalers like McKesson, AmerisourceBergen, Cardinal Health, and direct sales to hospital systems and specialty pharmacies]. These channels ensure broad market access and facilitate supply chain management across the United States. [Manufacturer Name] has established partnerships with [Mention any key distribution partners if applicable] to optimize reach within specialized therapeutic areas.
What is the Current Market Size and Growth Trajectory?
The current market for drugs treating [Disease/Condition] is estimated at $[Current Market Value] billion annually, with NDC 00378-6380 capturing approximately $[Product's Annual Revenue] million in sales in the most recent fiscal year ([Year of Revenue Data]). The overall market is projected to grow at a compound annual growth rate (CAGR) of [Market CAGR Percentage]% over the next five years, driven by an increasing prevalence of [Disease/Condition] cases. This growth is attributed to factors such as [List Growth Factor 1, e.g., an aging population, improved diagnostic capabilities] and [List Growth Factor 2, e.g., increased patient awareness, advancements in treatment guidelines]. [Manufacturer Name]'s product has maintained a consistent market share of [Market Share Percentage]% within this expanding segment.
What is the Competitive Landscape for NDC: 00378-6380?
The competitive landscape for NDC 00378-6380 is characterized by the presence of both branded and generic alternatives.
Key Competitor Products:
-
[Competitor Drug 1 Name] ([Generic Name/Chemical Class]):
- Manufacturer: [Competitor 1 Manufacturer Name]
- Mechanism of Action: [Competitor 1 MoA]
- Indication Overlap: [Yes/No]
- Market Share: Estimated [Competitor 1 Market Share]%
- Price Point: Generally [Higher/Lower/Comparable] to NDC 00378-6380.
-
[Competitor Drug 2 Name] ([Generic Name/Chemical Class]):
- Manufacturer: [Competitor 2 Manufacturer Name]
- Mechanism of Action: [Competitor 2 MoA]
- Indication Overlap: [Yes/No]
- Market Share: Estimated [Competitor 2 Market Share]%
- Price Point: Generally [Higher/Lower/Comparable] to NDC 00378-6380.
-
[Competitor Drug 3 Name] ([Generic Name/Chemical Class]):
- Manufacturer: [Competitor 3 Manufacturer Name]
- Mechanism of Action: [Competitor 3 MoA]
- Indication Overlap: [Yes/No]
- Market Share: Estimated [Competitor 3 Market Share]%
- Price Point: Generally [Higher/Lower/Comparable] to NDC 00378-6380.
Market Share Distribution:
| Product | Manufacturer | Estimated Market Share |
|---|---|---|
| NDC: 00378-6380 | [Manufacturer Name] | [Product Market Share]% |
| [Competitor Drug 1 Name] | [Competitor 1 Manufacturer] | [Competitor 1 Market Share]% |
| [Competitor Drug 2 Name] | [Competitor 2 Manufacturer] | [Competitor 2 Market Share]% |
| [Competitor Drug 3 Name] | [Competitor 3 Manufacturer] | [Competitor 3 Market Share]% |
| Other (<5% each) | Various | [Sum of other market shares]% |
The primary differentiator for NDC 00378-6380 remains its [Key Differentiator 1, e.g., superior efficacy in specific patient subgroups, favorable side effect profile, convenient dosing regimen]. However, emerging treatments with novel mechanisms of action are also entering the market, posing a future competitive threat.
What are the Patent Expiry and Generic Entry Timelines?
The principal patents covering NDC 00378-6380 are set to expire between [Year 1] and [Year 2]. Specifically, the core composition of matter patent is scheduled to expire on [Date of Patent Expiry 1]. Subsequent method of use and formulation patents are expected to expire on [Date of Patent Expiry 2] and [Date of Patent Expiry 3], respectively.
Based on historical generic drug approval timelines, the first generic entrants are anticipated by [Year of First Generic Entry]. The U.S. Patent and Trademark Office (USPTO) has granted exclusivity periods, with the latest likely expiration impacting market exclusivity around [Latest Exclusivity Expiration Year]. The availability of generics will significantly impact market dynamics and pricing. Generic manufacturers, such as [Example Generic Manufacturer 1] and [Example Generic Manufacturer 2], are expected to pursue Abbreviated New Drug Applications (ANDAs) for NDC 00378-6380 upon patent expiry.
What are the Price Trends and Projections for NDC: 00378-6380?
The current average wholesale price (AWP) for NDC 00378-6380 is approximately $[Current AWP] per [Unit, e.g., vial, tablet, box of 30 tablets]. Over the past three years, the product has experienced an average annual price increase of [Average Annual Price Increase Percentage]%. This trend is primarily driven by manufacturer pricing strategies, R&D investment recovery, and the absence of direct generic competition.
Projected Price Trends (Next 5 Years):
| Year | Projected AWP | Notes |
|---|---|---|
| [Current Year] | $[Current AWP] | Baseline pricing. |
| [Year + 1] | $[Year+1 AWP] | Continued moderate increase due to inflation and market demand. |
| [Year + 2] | $[Year+2 AWP] | Potential for steeper increase prior to significant generic entry. |
| [Year + 3] | $[Year+3 AWP] | Significant price erosion anticipated with multiple generic approvals. |
| [Year + 4] | $[Year+4 AWP] | Further price compression as generics gain market share. |
| [Year + 5] | $[Year+5 AWP] | Stabilized pricing at a lower level, dominated by generics. |
The introduction of generic versions in [Year of First Generic Entry] is projected to lead to a rapid decline in the average selling price (ASP) of branded NDC 00378-6380, likely by [Projected ASP Reduction Percentage]% within the first year of generic availability. The overall market value for the therapeutic category, however, is expected to maintain growth due to increasing patient volumes.
What are the Reimbursement Policies and Payer Landscape?
Reimbursement for NDC 00378-6380 is primarily governed by Medicare Part D, Medicaid, and commercial health insurance plans. The drug is typically classified as a [Formulary Tier, e.g., Tier 3 preferred brand, Tier 4 non-preferred brand] on most formularies. Prior authorization requirements are common, necessitating documentation of treatment failure with lower-cost alternatives or confirmation of specific disease severity criteria.
Major payers, including [Payer 1, e.g., UnitedHealthcare], [Payer 2, e.g., CVS Health/Aetna], and [Payer 3, e.g., Cigna], influence market access through their formulary decisions and utilization management programs. The Centers for Medicare & Medicaid Services (CMS) also plays a role through its reimbursement rates and negotiation power. The increasing scrutiny on drug pricing by payers is likely to exert downward pressure on both branded and, to a lesser extent, generic prices post-exclusivity. Value-based agreements are also emerging as a trend, potentially impacting future pricing structures.
What are the Opportunities and Threats?
Opportunities:
- Expansion into New Indications: Investigating and obtaining approval for new therapeutic indications could significantly extend the product's market life and revenue stream.
- Geographic Market Expansion: Untapped or underserved international markets present opportunities for increased sales volume.
- Combination Therapies: Research into synergistic effects with other therapeutic agents may lead to novel treatment regimens and expanded market reach.
- Biosimilar Development (if applicable): For biologic products, the advent of biosimilars can create new market dynamics and potentially extend product life cycles through authorized generics.
Threats:
- Generic Competition: The primary threat is the inevitable entry of generic competitors upon patent expiry, leading to substantial price erosion.
- Emergence of Novel Therapies: The development of disruptive technologies or treatments with superior efficacy or safety profiles can rapidly diminish market share.
- Payer Restrictions and Formulary Exclusions: Increasingly stringent reimbursement policies and formulary limitations can restrict patient access and physician prescribing.
- Regulatory Changes: Shifts in FDA regulations, pricing oversight, or manufacturing standards can impact market access and profitability.
Key Takeaways
- NDC 00378-6380 is established in the [Therapeutic Area] market, driven by [Primary Demand Driver].
- A strong competitive set exists, with [Competitor Drug 1] and [Competitor Drug 2] representing key rivals.
- Patent expiry is anticipated in [Year of First Generic Entry], with immediate and significant price erosion expected.
- Projected price trends indicate a sharp decline post-generic entry, stabilizing at a lower ASP.
- Reimbursement is subject to payer policies and utilization management, with increasing pressure on pricing.
Frequently Asked Questions
1. When is the earliest a generic version of NDC: 00378-6380 is expected to be available?
The earliest anticipated generic entry is [Year of First Generic Entry], contingent on patent challenges and regulatory approval timelines.
2. What is the current average wholesale price (AWP) and how has it trended?
The current AWP is approximately $[Current AWP] per [Unit]. It has shown an average annual increase of [Average Annual Price Increase Percentage]% over the past three years.
3. Which are the primary payers influencing access to this drug?
Major payers include UnitedHealthcare, CVS Health/Aetna, Cigna, and Medicare Part D programs.
4. Beyond generic competition, what other significant threats exist for NDC: 00378-6380?
Emerging novel therapies with superior profiles and increasingly restrictive payer formulary management pose significant threats.
5. Are there opportunities for market expansion beyond the current indications?
Yes, opportunities exist in pursuing new therapeutic indications and expanding into underserved international markets.
Citations
[1] Smith, J. et al. (2020). Efficacy and Safety of [Drug Name] in Patients with [Disease]. Journal of Pharmaceutical Research, 45(3), 112-128. [Note: This is a placeholder citation. Actual citations would be specific to the drug and its clinical studies.]
More… ↓
